Celcuity Q4 2025 Earnings Call Highlights: Navigating Losses Amidst Promising Drug Development Milestones

Celcuity Inc reported a net loss of $177 million for FY2025, driven by increased research and development expenses and general administrative expenses. Despite this, the company achieved significant clinical and regulatory milestones, including the FDA's acceptance of their new drug application for gedatolisib with a priority review. Gedatolisib demonstrated a favorable safety profile and unprecedented efficacy data in the Phase 3 VICTORIA-1 trial. Celcuity has a strong financial position with $441.5 million in cash and investments, expected to finance operations through 2027.